Natco Pharma gets American drug regulator's nod for generic cancer treatment drug

Natco, along with its marketing partner Arrow International previously settled the Paragraph IV litigation related to the product with Celgene, now part of Bristol-Myers Squibb, who sells the product under the brand name 'Revlimid', it added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3ucmcJt
via IFTTT